Goro Honda
   Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine
   Position   Professor and Division head
Article types Original article
Language English
Peer review Non peer reviewed
Title Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study).
Journal Formal name:Trials
Abbreviation:Trials
ISSN code:17456215/17456215
Domestic / ForeginForegin
Volume, Issue, Page 23(1),pp.119
Author and coauthor Yamamoto Tomohisa, Fujii Tsutomu, Hirano Satoshi, Motoi Fuyuhiko, Honda Goro, Uemura Kenichiro, Kitayama Joji, Unno Michiaki, Kodera Yasuhiro, Yamaue Hiroki, Shimokawa Toshio, Hashimoto Daisuke, Yamaki So, Yoshitomi Hideyuki, Miura Fumihiko, Ueno Hideki, Sekimoto Mitsugu, Satoi Sohei,
Publication date 2022/02
Summary The prognosis of pancreatic ductal carcinoma (PDAC) with peritoneal metastasis remains dismal. Systemic chemotherapy alone may not be effective, and the combination of intraperitoneal chemotherapy with systemic chemotherapy is expected to prolong the overall survival in patients with peritoneal metastasis. We have designed a randomized phase III trial to confirm the superiority of intravenous (i.v.) and intraperitoneal (i.p.) paclitaxel (PTX) with S-1 relative to gemcitabine plus nab-PTX (GnP), which is the current standard therapy for patients with metastatic PDAC. A total of 180 patients will be accrued from 30 institutions within 3 years. Patients will be randomly assigned in a 1:1 ratio to receive either i.v. and i.p. PTX with S-1 or GnP (target of 90 patients per group). The primary endpoint is overall survival; secondary endpoints are progression-free survival, response rate, proportion with negative peritoneal washing cytology during chemotherapy, proportion requiring conversion surgery, and adverse event profiles. Japan Registry of Clinical Trials jRCTs051180199 ( https://jrct.niph.go.jp/ ).
DOI 10.1186/s13063-022-06049-7
PMID 35123553